Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Keratosis, Actinic 6Carcinoma, Basal Cell 2Skin Diseases 1Precancerous Conditions 1Neoplasms, Basal Cell 1Keratosis 1Hutchinson's Melanotic Freckle 1

Interventions

binimetinib 2Sodium Chloride 2Aminolevulinic Acid 2palbociclib 1methyl 5-aminolevulinate 1ipatasertib 1exemestane 1encorafenib 1baricitinib 1atezolizumab 1Vemurafenib 1VP-102 1Trabectedin 1Spironolactone 1Radiotherapy 1Radiation 1Photochemotherapy 1Paclitaxel 1Low-Level Light Therapy 1Leuprolide 1Injections, Intradermal 1Gonadotropin-Releasing Hormone 1Fluorouracil 1Floderm topical cream 1Everolimus 1Equipment and Supplies 1Docetaxel 1Dacarbazine 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Skin Diseases × BF-200 ALA × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡